LeydenLabs-SM-Feb2024-Publication-021624-v01-2

February 16, 2024

New publication shows CR9114 protects against avian flu in mice

The ongoing spread of avian flu among animals has increased the urgency of developing products that could prevent infection in the event of an H5N1 pandemic. A new study by Leyden Labs, published in Nature’s Scientific Reports, shows that the CR9114 antibody can protect intranasally at low dosages against H5N1 in vivo. Read it here.

The study found that CR9114, delivered intranasally, fully protected against H5N1 infection in vivo. By contrast, vaccination with the seasonal quadrivalent influenza vaccine with H1, H3, B/Yam and B/Vic antigen, did not cross-protect mice from H5N1 challenge. Furthermore, CR9114 neutralized 10 different strains of H5 influenza in vitro, further confirming its breadth of potential protection. 

Broad protection is critical amid pandemic situations, when there’s no way to know in advance which strain will predominate. CR9114 uniquely targets a highly conserved epitope of flu viruses allowing this broadly protective quality. At Leyden Labs, we remain focused on the discovery, optimization, and development of antibodies that can deliver broad and immediate protection to combat respiratory viral threats.

LL-Blue

OUR NEW APPROACH  |  OUR TEAM  |  JOIN OUR MISSION   |  NEWS  |  CAREERS  

Contact

Media inquiries

Stay updated

Leyden Laboratories B.V.

Leiden Laboratory
Emmy Noetherweg 2
2333 BK  Leiden
The Netherlands


Leyden Laboratories Co.

Boston Laboratory
201 Dexter Avenue
Watertown
MA 02472
United States


Leyden Labs, S.L.

Granada Office
Avda. del Conocimiento 41.A210
Centro de Empresas
Parque Tecnológico de la Salud
18016 Granada
Spain


© Leyden Labs, 2023  |  Privacy Statement  |  Design by Ape to Zebra

Back to top Arrow